Repatha vs Losartan: What to Do When One Fails

Why These Two Drugs Are Rarely Interchangeable

Evolocumab and losartan are not competitors in the same pharmacological lane. Repatha targets hepatic PCSK9, preventing LDL receptor degradation and driving circulating LDL-C down [1]. Losartan blocks the AT1 receptor, blunting vasoconstriction and aldosterone release to reduce blood pressure [2]. A patient whose LDL-C is out of control does not benefit from switching to an ARB. A patient whose BP remains uncontrolled does not benefit from adding a PCSK9 inhibitor unless they also carry dyslipidemia.

The reason clinicians ask "Repatha vs losartan" is usually one of two scenarios:

1. A patient is on both drugs for combined cardiometabolic risk and one is failing.
2. A clinician is building a preventive regimen and needs to prioritize which problem to treat first.

Both scenarios require understanding what "failure" means for each agent specifically.

What Counts as Repatha Failure

The ACC/AHA 2018 Cholesterol Guideline defines LDL-C failure as remaining above the risk-appropriate threshold after maximally tolerated statin therapy plus ezetimibe [3]. Evolocumab is added at that point. If LDL-C still sits above goal on evolocumab 140 mg every 2 weeks or 420 mg monthly, the drug has failed, but only after confirming the injection was actually administered and that a secondary cause of hypercholesterolemia (hypothyroidism, nephrotic syndrome) has been excluded.

What Counts as Losartan Failure

Losartan 100 mg daily is the ceiling dose. If systolic BP remains above 130 mmHg (per ACC/AHA 2017 criteria) [4] on that dose in a fully adherent patient, losartan monotherapy has failed. Losartan also fails pharmacokinetically in roughly 6 to 8% of patients who are poor CYP2C9 metabolizers and cannot convert the prodrug to its active metabolite E-3174 [5].

The FOURIER Data: What Repatha Can and Cannot Do

In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks added to statin therapy reduced LDL-C by a median of 59% (from 92 mg/dL to 30 mg/dL) and cut the composite of MI, stroke, and cardiovascular death by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years [1]. The absolute risk reduction was 1.5 percentage points.

What FOURIER Did Not Show

FOURIER enrolled patients with established ASCVD on background statin therapy. It did not enroll hypertension-only patients. Blood pressure was not a primary outcome. Evolocumab produced no meaningful change in systolic BP, which is expected given its mechanism has no vasomotor component [1].

Patients Most Likely to Benefit from Repatha

The FOURIER subgroup analysis published in JACC showed the largest absolute benefit in patients with prior MI within 2 years, polyvascular disease, or diabetes: those with two or more high-risk features had an ARR of 3.4% vs 0.4% in lower-risk subgroups [6]. If a patient's primary unmet need is LDL reduction in that high-risk context, staying on evolocumab and troubleshooting the failure mode is almost always preferable to stopping.

The LIFE Data: What Losartan Can and Cannot Do

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial (N=9,193) randomized hypertensive patients with LVH to losartan 50 to 100 mg vs atenolol 50 to 100 mg [2]. Losartan reduced the primary composite endpoint (CV death, MI, stroke) by 13% (RR 0.87, 95% CI 0.77 to 0.98) and reduced new-onset diabetes by 25% compared with atenolol [2].

Losartan's LDL-C Effect

Losartan has no direct mechanism for LDL-C reduction. The LIFE trial did not show a clinically meaningful change in total cholesterol or LDL-C between arms [2]. A patient on losartan whose LDL-C is elevated still needs a statin or PCSK9 inhibitor.

When Losartan Must Stop

Three stopping criteria appear consistently in prescribing data and the FDA label [7]:

• Serum potassium above 5.5 mEq/L on two consecutive readings
• eGFR decline greater than 30% from baseline within 4 months of initiation in the absence of volume depletion
• Bilateral renal artery stenosis confirmed on imaging

When losartan stops for any of these reasons, the replacement choice depends on the BP goal still outstanding, a calcium channel blocker (amlodipine) or a thiazide-like diuretic (chlorthalidone) typically comes next, not a PCSK9 inhibitor.

Step-by-Step: When Repatha Fails

Step 1. Confirm Adherence

Self-injection adherence with evolocumab runs approximately 80 to 85% at 12 months in real-world registries, compared with 96% in the controlled FOURIER protocol [8]. Before labeling a patient a non-responder, review pharmacy refill records and ask directly whether injections are being administered on schedule.

Step 2. Recheck Fasting LDL-C Properly

A non-fasting LDL-C can overestimate circulating LDL by 10 to 15 mg/dL due to VLDL remnants [9]. Recheck with a fasting lipid panel before concluding the drug is failing.

Step 3. Rule Out Secondary Hypercholesterolemia

Hypothyroidism raises LDL-C by reducing hepatic LDL receptor expression. TSH should be checked in any patient whose LDL-C fails to reach goal despite adherent PCSK9 inhibitor therapy. Nephrotic syndrome, cholestasis, and anorexia nervosa also raise LDL-C through separate mechanisms [10].

Step 4. Escalate or Combine

If adherence is confirmed and secondary causes are excluded, two options exist:

1. Add ezetimibe 10 mg daily if not already on board. The IMPROVE-IT trial (N=18,144) showed ezetimibe added to simvastatin reduced LDL-C by an additional 24% and reduced cardiovascular events by 6.4% relative to simvastatin alone [11].
2. Switch to alirocumab (Praluent), the only other approved PCSK9 inhibitor. Head-to-head pharmacodynamic data are limited, but alirocumab 150 mg every 2 weeks achieves a similar 60% LDL-C reduction and carries the same mechanism [12].

Adding or switching to an ARB like losartan serves no purpose in this scenario unless the patient also has uncontrolled hypertension.

Step-by-Step: When Losartan Fails

Step 1. Maximize the Dose First

Many patients are initiated on losartan 25 to 50 mg and never titrated. The antihypertensive effect of losartan is dose-dependent up to 100 mg daily; moving from 50 mg to 100 mg produces an additional 5 to 7 mmHg systolic reduction on average [13].

Step 2. Assess for Poor CYP2C9 Metabolism

As noted above, 6 to 8% of patients carry CYP2C9 poor-metabolizer variants (*2/*2, *2/*3, *3/*3) and generate substantially less active E-3174 metabolite from a given losartan dose [5]. Pharmacogenomic testing is available and may explain apparent non-response. Switching to valsartan or irbesartan (not CYP2C9-dependent) is a practical alternative in this context [14].

Step 3. Add a Second Antihypertensive

JNC 8 and ACC/AHA 2017 guidelines support combination therapy for patients more than 20 mmHg above their systolic target [4]. Adding amlodipine 5 to 10 mg or chlorthalidone 12.5 to 25 mg to losartan is evidence-supported by the ACCOMPLISH trial (N=11,506), where benazepril plus amlodipine reduced CV events by 19.6% compared with benazepril plus HCTZ [15].

Step 4. Consider an ACE Inhibitor in Specific Populations

For patients with diabetic nephropathy or proteinuria, switching from losartan to an ACE inhibitor (e.g., ramipril) or using both classes (with careful monitoring) may provide additional renoprotection. The RENAAL trial (N=1,513) showed losartan reduced the risk of doubling serum creatinine by 25% vs placebo in type 2 diabetic nephropathy [16], but some patients progress despite ARB therapy and require ACE inhibitor addition under nephrology co-management.

Adding evolocumab at this stage is appropriate only if LDL-C is separately out of goal, not as a substitute for blood pressure management.

Combined Cardiometabolic Risk: Using Both Drugs Together

A patient with established ASCVD, LDL-C of 85 mg/dL on maximally tolerated statin, and a systolic BP of 148 mmHg is a candidate for both drugs simultaneously. The 2019 ACC/AHA Primary Prevention Guideline notes that the 10-year ASCVD risk calculation should drive shared decision-making for preventive therapies [17]. For a patient at 15% or higher 10-year risk, addressing both LDL-C and BP is not redundant, it is additive for absolute risk reduction.

The Systolic Blood Pressure Intervention Trial (SPRINT, N=9,361) demonstrated that targeting systolic BP below 120 mmHg reduced the primary composite CV endpoint by 25% (HR 0.75, P<0.001) relative to the 140 mmHg target [18]. When combined with evolocumab's 15% relative risk reduction from FOURIER, the two agents together may reduce a patient's residual risk more than either alone.

Monitoring Parameters When Both Are Prescribed

Prescribing both agents introduces two separate monitoring tracks:

• Evolocumab: fasting LDL-C at 4 to 12 weeks after initiation or dose change, then annually once stable [3]
• Losartan: serum creatinine, BMP (potassium in particular), and BP at 2 to 4 weeks after any dose change, then every 3 to 6 months [7]

Neither drug significantly alters the monitoring requirements for the other. The drugs do not share a pharmacokinetic interaction of clinical relevance.

Should You Switch from Repatha to Losartan (or Vice Versa)?

A direct substitution of one for the other is almost never appropriate. The question "should I switch from Repatha to Losartan?" usually signals a misunderstanding of what each drug does, or a cost-driven inquiry.

The Cost Angle

Evolocumab carries a list price near $5,800 per year before rebates and prior authorization, while generic losartan 100 mg runs under $30 per year [19]. If a patient is being asked to choose between the two due to cost, that conversation should happen with a prescriber who can assess which risk factor, uncontrolled LDL-C or uncontrolled BP, poses the greater near-term threat to the individual patient.

The ACC/AHA 2018 Cholesterol Guideline states: "For patients in whom a PCSK9 inhibitor is being considered, a clinician-patient discussion of the potential for cardiovascular benefit, side effects, drug availability, and cost is recommended (Class I recommendation)" [3]. That discussion does not frame losartan as an alternative to evolocumab; it frames cost as a shared-decision consideration within the LDL-C management track.

When Stopping Repatha Is Clinically Justified

Stopping evolocumab (without replacing it with losartan) may be appropriate if:

• The patient has had a sustained LDL-C below 40 mg/dL and the treating physician and patient jointly decide the residual benefit is marginal relative to injection burden
• A new contraindication arises (pregnancy is a relative contraindication given limited safety data)
• Severe injection-site reactions persist despite rotating sites and technique coaching

In all three scenarios, the next step for LDL-C management is re-titration of statin dose or addition of ezetimibe, not losartan.

Clinical Decision Framework: Repatha vs Losartan Failure Summary

The table below summarizes the decision logic for each failure scenario.

| Failure Scenario | First Check | Next Agent | Not Appropriate | |---|---|---|---| | Repatha: LDL-C above goal | Adherence, fasting sample, TSH | Ezetimibe or alirocumab | Losartan | | Repatha: injection intolerance | Rotate sites, reassess technique | Alirocumab | Losartan | | Losartan: BP above goal | Dose at 100 mg? CYP2C9 status? | Amlodipine or chlorthalidone | Evolocumab | | Losartan: hyperkalemia | Dietary potassium, concurrent K-sparing drugs | Amlodipine or CCB class switch | Evolocumab | | Losartan: renal decline | Rule out RAS, assess volume status | Nephrology consult, CCB | Evolocumab |